A novel genre of diazoniumdiolate molecules, characterized by controlled release of nitric oxide (NO), was developed for the treatment of hypertension. This presentation will describe the in vitro and in vivo metabolism studies that enabled the build of the unique biotransformation-triggered time-delayed mechanism of NO release from these diazoniumdiolate molecules, culminating in the identification of MK-8150 as a clinical candidate. Additionally, the presentation will discuss the non-traditional PK/PD approach used to translate preclinical data to humans and the resulting outcome from human studies with MK-8150.<br/>

Programed release of nitric oxide, via oxidative metabolism, in animals and humans from clinical candidate MK-8150

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.